Sarepta Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
SRPT$16.42-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| BALANCE AT DECEMBER 31, 2021 | 87,127 | $9 | $4,134,768 | $(20) | $(3,206,748) | $928,009 |
| Exercise of options for common stock | 318 | — | 22,573 | — | — | 22,573 |
| Vest of restricted stock units | 389 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 116 | — | 7,470 | — | — | 7,470 |
| Stock-based compensation | — | — | 233,018 | — | — | 233,018 |
| Purchase of capped call share options for 2027 Notes | — | — | (127,305) | — | — | (127,305) |
| Partial settlement of capped call share options for 2024 Notes | — | — | 26,317 | — | — | 26,317 |
| Unrealized losses from available-for-sale securities, net of tax | — | — | — | (1,644) | — | (1,644) |
| Net loss | — | — | — | — | (703,488) | (703,488) |
| BALANCE AT DECEMBER 31, 2022 | 87,950 | 9 | 4,296,841 | (1,664) | (3,910,236) | 384,950 |
| Exercise of options for common stock | 528 | — | 40,485 | — | — | 40,485 |
| Vest of restricted stock units | 645 | — | — | — | — | — |
| Issuance of common stock for exchange of 2024 Notes | 4,456 | — | 693,377 | — | — | 693,377 |
| Partial settlement of capped call share options for 2024 Notes | — | — | 80,645 | — | — | 80,645 |
| Issuance of common stock under employee stock purchase plan | 153 | — | 10,761 | — | — | 10,761 |
| Stock-based compensation | — | — | 182,514 | — | — | 182,514 |
| Unrealized gains from available-for-sale securities, net of tax | — | — | — | 2,582 | — | 2,582 |
| Net loss | — | — | — | — | (535,977) | (535,977) |
| BALANCE AT DECEMBER 31, 2023 | 93,732 | 9 | 5,304,623 | 918 | (4,446,213) | 859,337 |
| Exercise of options for common stock | 850 | 1 | 67,319 | — | — | 67,320 |
| Vest of restricted stock units | 734 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 143 | — | 12,205 | — | — | 12,205 |
| Issuance of common stock for conversion of 2024 Notes | 1,441 | — | 105,757 | — | — | 105,757 |
| Modification of 2017 Capped Calls | — | — | 43,887 | — | — | 43,887 |
| Stock-based compensation | — | — | 205,133 | — | — | 205,133 |
| Unrealized losses from available-for-sale securities, net of tax | — | — | — | (1,136) | — | (1,136) |
| Net income | — | — | — | — | 235,239 | 235,239 |
| BALANCE AT DECEMBER 31, 2024 | 96,900 | $10 | $5,738,924 | $(218) | $(4,210,974) | $1,527,742 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.